bs_bs_banner
International Journal of Urology (2014) 21, 1114–1119
doi: 10.1111/iju.12532
Original Article: Clinical Investigation
Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma Koji Mitsuzuka, Shinichi Yamashita, Shunichi Namiki, Shigeyuki Yamada, Ko Sato, Hideo Saito, Yasuhiro Kaiho, Akihiro Ito, Haruo Nakagawa and Yoichi Arai Department of Urology, Tohoku University School of Medicine, Sendai, Miyagi, Japan
Abbreviations & Acronyms AUC = area under the curve BSC = best supportive care ECOG-PS = Eastern Cooperative Oncology Group Performance Status GC = gemcitabin/cisplatin GCa = gemcitabin/carboplatin MVAC = methotrexate/ vinblastin/adriamycin/cisplatin RT = radiation therapy UC = urothelial carcinoma Correspondence: Koji Mitsuzuka M.D., Ph.D., Department of Urology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. Email: [email protected] Received 24 November 2013; accepted 11 May 2014. Online publication 24 June 2014
Objectives: To examine whether low-dose maintenance gemcitabine-carboplatin chemotherapy is beneficial for patients with metastatic urothelial carcinoma. Methods: We retrospectively reviewed the records of 36 patients with metastatic urothelial carcinoma who received first-line chemotherapy (gemcitabine/cisplatin, gemcitabine/carboplatin, or methotrexate/vinblastine/adriamycin/cisplatin) between 2006 and 2012. Those who had responded, but were unable to tolerate ongoing first-line chemotherapy, had been switched to low-dose maintenance chemotherapy consisting of 1 g/m2 of gemcitabine and area under the curve 2–4 of carboplatin given on day 1 of a 6-week cycle, and were continued unless disease progression was seen. Results: After a median of three cycles of first-line chemotherapy, 17 patients had been switched to low-dose maintenance chemotherapy. The median age was 70 years (range 56–79 years), and 12 patients (70.6%) had renal dysfunction (creatinine clearance
International Journal of Urology (2014) 21, 1114–1119
doi: 10.1111/iju.12532
Original Article: Clinical Investigation
Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma Koji Mitsuzuka, Shinichi Yamashita, Shunichi Namiki, Shigeyuki Yamada, Ko Sato, Hideo Saito, Yasuhiro Kaiho, Akihiro Ito, Haruo Nakagawa and Yoichi Arai Department of Urology, Tohoku University School of Medicine, Sendai, Miyagi, Japan
Abbreviations & Acronyms AUC = area under the curve BSC = best supportive care ECOG-PS = Eastern Cooperative Oncology Group Performance Status GC = gemcitabin/cisplatin GCa = gemcitabin/carboplatin MVAC = methotrexate/ vinblastin/adriamycin/cisplatin RT = radiation therapy UC = urothelial carcinoma Correspondence: Koji Mitsuzuka M.D., Ph.D., Department of Urology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. Email: [email protected] Received 24 November 2013; accepted 11 May 2014. Online publication 24 June 2014
Objectives: To examine whether low-dose maintenance gemcitabine-carboplatin chemotherapy is beneficial for patients with metastatic urothelial carcinoma. Methods: We retrospectively reviewed the records of 36 patients with metastatic urothelial carcinoma who received first-line chemotherapy (gemcitabine/cisplatin, gemcitabine/carboplatin, or methotrexate/vinblastine/adriamycin/cisplatin) between 2006 and 2012. Those who had responded, but were unable to tolerate ongoing first-line chemotherapy, had been switched to low-dose maintenance chemotherapy consisting of 1 g/m2 of gemcitabine and area under the curve 2–4 of carboplatin given on day 1 of a 6-week cycle, and were continued unless disease progression was seen. Results: After a median of three cycles of first-line chemotherapy, 17 patients had been switched to low-dose maintenance chemotherapy. The median age was 70 years (range 56–79 years), and 12 patients (70.6%) had renal dysfunction (creatinine clearance
